New scientific literature supports the use of Brucellacapt® in the treatment follow-up of the disease
Brucellosis is still common in the Mediterranean region, the Middle East, Central Asia and parts of Latin America. Over the last ten years, the infection has re-emerged, with high prevalence in other countries and, in particular, in Eastern Europe, the Balkans, and Eurasia. Brucella melitensis infection is recognized as a significant public health challenge, with a major economic and financial burden in countries where the disease remains endemic.
B.melitensis is very contagious for humans and the disease, unless diagnosed and treated both promptly and effectively, can become chronic, affecting multiple body systems. However, the brucellosis is designated by WHO as a “neglected” zoonosis. While basic science and epidemiology of human brucellosis is known, it is often under-detected and therefore under-reported despite inflicting a high burden of disease
The diagnosis of the illness is based on laboratory testing together with the clinical evaluation of the patient. The serological diagnosis is, for several reasons the most widely used technology and BRUCELLACAPT® is considered as a recommended alternative to confirm clinical suspicions and also to assess the evolution of an infection and to diagnose relapses. BRUCELLACAPT®, in an easy and simple way, allows for the detection of antibodies from advanced stages of the illness. This product has been specially design for the diagnosis of chronic brucellosis.
However, as Bosilkovski M. et al. shows, BRUCELLACAPT® is not only an ideal technique for the diagnosis of evolved phases of brucellosis, but also for its control once the patient begins the treatment for the illness. This study performed in Macedonia including 132 patients, tries to evaluate the utility of BRUCELLACAPT® for the follow-up of the disease in a 15 month period.
The results of this study show that a rapid reduction of BRUCELLACAPT® titers, together with an improvement in clinical parameters is a good indicator of patient recovery. The determination of Brucella specific IgG antibody titers is always a key marker of active infection.
An electronic copy of the mentioned article can be directly downloaded here or through our Bibliography section.